{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Central quality assurance review of the IMRT planning and dosing categorized unacceptable deviations (UD) from protocol compliance with the delineation of planning target volume for the vagina and pelvic lymph nodes. Each arm of this study is considered independently, they are not compared to each other. The study was designed such that, for each arm, 5 or more of 42 subjects scored as unacceptable would determine the respective treatment technique as not reproducible. For each arm this design provides 90% power with a 0.05 type I error to reject the null hypothesis that the true probability of concluding the given technique to be reproducible is \\<= 80%. The alternative hypothesis is that the true probability is \\>= 95%.\n\nFor \\[vagina / pelvic lymph nodes\\]: UD is defined as: The 90% isodose surface covers \\< 95% of \\[internal target volume (ITV)/ planned target volume (PTV)\\] 50.4 or \\> 5% of the \\[ITV/PTV\\] 50.4 receives over 115%.","groups":[{"description":"Endometrial Cancer patients receive Intensity Modulated Radiation Therapy (IMRT)","id":"OG000","title":"Endometrial Cancer: IMRT"},{"description":"Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) + Chemotherapy (cisplatin)","id":"OG001","title":"Cervical Cancer: IMRT + Chemotherapy (Cisplatin)"}],"paramType":"NUMBER","populationDescription":"All eligible patients.","reportingStatus":"POSTED","timeFrame":"IMRT planning and dosing data is centrally reviewed for quality assurance after treatment delivery.","title":"Reproducibility of Radiation Technique (Number of Unacceptable Deviations in Central IMRT Quality Assurance Review)","type":"PRIMARY","unitOfMeasure":"participants"}